Gordon Research Conferences
PI_Conferences PI_Conferences_Past
Conference Program
 
Tuberculosis Drug Development
July 3-8, 2011
Renaissance Tuscany Il Ciocco Resort
Lucca (Barga), Italy

The 2011 Gordon Research Conference on Tuberculosis Drug Development will cover the range of activities involved in discovering and producing new drugs. With the realization that target-based screening for anti-bacterial agents has been disappointing, and that druggable targets are scarce, this GRC will also reassess the approaches involved. The conference will present new enabling technologies, address target and compound discovery, discuss new candidate drugs in development, highlight clinical trial design and share early trial results while also considering alternative approaches to tuberculosis treatment. We invite researchers interested in all of these aspects of drug development to attend and welcome participants from academia, industry, government and non-governmental organizations. In particular, we invite trainees and scientists from TB-endemic countries to apply as their contribution to the struggle against TB is especially important. All participants are asked to submit abstracts of their work for presentation as posters and some of these abstracts will be chosen for oral presentations. The conference provides the opportunity to interact with colleagues in an informal and intimate atmosphere and is designed to promote extensive discussion. In the past, the meeting has been oversubscribed - please apply early!


SUNDAY
4:00 pm - 8:00 pmArrival and Check-in (Check-in Desk Closed 6:00 pm - 7:45 pm)
6:00 pmDinner
7:30 pm - 7:40 pmWelcome / Introductory Comments by GRC Site Staff
7:40 pm - 9:30 pmTargeting drug-resistant tuberculosis
Discussion Leader: Stewart Cole (EPFL)
7:40 pm - 8:20 pm Mario Raviglione (Stop TB, WHO)
"Global TB targets"
8:20 pm - 8:35 pm Discussion
8:35 pm - 9:15 pm Floyd Romesberg (Scripps Research Institute)
"Why are there so few drug targets?"
9:15 pm - 9:30 pm Discussion
MONDAY
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmPotential new targets for drug discovery
Discussion Leader: Sabine Ehrt (Cornell University)
9:00 am - 9:25 am Jun-Rong Wei (Harvard School of Public Health)
"New approaches to target validation"
9:25 am - 9:35 am Discussion
9:35 am - 9:50 am Luke Alderwick (University of Birmingham)
"The Ethambutol target-EmbC is a Lectin-like Carbohydrate Binding Module"
9:50 am - 10:00 am Discussion
10:00 am Coffee Break / Group Photo
10:30 am - 10:55 am Mamadou Daffe (CNRS Toulouse)
"Targeting FadD32 & PKS13"
10:55 am - 11:05 am Discussion
11:05 am - 11:30 am Mary Jackson (Colorado State University)
"Potency and mode of action of adamantyl ureas against M. tuberculosis"
11:30 am - 11:40 am Discussion
11:40 am - 12:15 pm Yap Boum (Epicentre Mbara Research Base)
"Antimicrobial compounds targeting the unique reaction mechanism of thymidylate synthase ThyX"
12:15 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 5:30 pmFree Time
5:30 pm - 7:30 pmMetabolism as a target
Discussion Leader: John Blanchard (Albert Einstein College of Medicine)
5:30 pm - 5:55 pm Gregory Cook (University of Otago)
"The VapBC toxin-antitoxin regulates metabolic flux in M. smegmatis by targeting mRNA transcripts that transport and metabolize sugars"
5:55 pm - 6:10 pm Discussion
6:10 pm - 6:35 pm Kyu Rhee (Cornell University)
"Metabolomics"
6:35 pm - 6:45 pm Discussion
6:45 pm - 7:20 pm Pedro Alzari (Institut Pasteur)
"Protein kinases and central metabolism"
7:20 pm - 7:30 pm Discussion
8:00 pmDinner
TUESDAY
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmNew approaches/new leads
Discussion Leader: Tanya Parish (Infectious Disease Research Institute)
9:00 am - 9:25 am Claudia Sala (EPFL)
"New models for latency drug discovery"
9:25 am - 9:35 am Discussion
9:35 am - 9:50 am Shekhar Mande (Centre For DNA Fingerprinting and Diagnostics)
"Genome-wide interactions and communication signals during mycobacterial latency"
9:50 am - 10:00 am Discussion
10:00 am Coffee Break
10:30 am - 10:55 am Carl Nathan (Cornell University)
"Killing non-replicating M. tuberculosis"
10:55 am - 11:10 am Discussion
11:10 am - 11:35 am Charles Thompson (University of British Columbia)
"Synergistic drug combinations for tuberculosis therapy identified by a novel high throughput screen"
11:35 am - 11:45 am Discussion
11:45 am - 12:20 pm David Sherman (Seattle Biomedical Research Institute)
"Integrated methods for TB drug discovery"
12:20 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 5:30 pmPoster Session I
5:30 pm - 7:30 pmScreening for new antibiotics
Discussion Leader: Stewart Cole (EPFL)
5:30 pm - 5:55 pm Helena Boshoff (NIAID)
"New screening approaches"
5:55 pm - 6:10 pm Discussion
6:10 pm - 6:25 pm Lixin Zhang (Institute of Microbiology, Beijing)
"Bioprospecting natural products for potential anti-TB drugs"
6:25 pm - 6:35 pm Discussion
6:35 pm - 7:10 pm Mike Foley (Broad Institute)
"Diversity oriented synthesis and screening"
7:10 pm - 7:30 pm Discussion
8:00 pmDinner
WEDNESDAY
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmNew compounds/delivery systems
Discussion Leader: Véronique Dartois (Novartis Institute for Tropical Disease)
9:00 am - 9:25 am Ute Moellmann (Alere Technologies GmbH, Jena)
"1,4 Benzothiazinones - preclinical development"
9:25 am - 9:35 am Discussion
9:35 am - 9:50 am Giancarlo Biagini (Liverpool School of Tropical Medicine)
"Targeting the type II NADH:menaquinone oxidoreductase of Mycobacterium tuberculosis: towards a novel drug against latent infection"
9:50 am - 10:00 am Discussion
10:00 am Coffee Break
10:30 am - 11:10 am Alfonso Mendoza (GSK)
"InhA: Old target, new drugs"
11:10 am - 11:30 am Discussion
11:30 am - 12:10 pm Jacques Grosset (Johns Hopkins Medical School)
"Optimizing dosing and animal models"
12:10 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 5:30 pmPoster Session II
5:30 pm - 7:30 pmAdjuncts to TB therapy
Discussion Leader: Gilla Kaplan (Public Health Research Institute, Newark)
5:30 pm - 5:55 pm Thomas Hawn (Washington University, Seattle)
"Host susceptibility genes"
5:55 pm - 6:10 pm Discussion
6:10 pm - 6:35 pm David Tobin (Duke University)
"Eicosanoid balance and TB susceptibilty"
6:35 pm - 6:45 pm Discussion
6:45 pm - 7:20 pm Kanury V.S. Rao (ICGEB, New Delhi)
"Targeting the macrophage machinery aiding M. tuberculosis"
7:20 pm - 7:30 pm Discussion
7:30 pm - 8:00 pmBusiness Meeting
Nominations for the next Vice Chair; Fill out Conference Evaluation Forms; Discuss future Site & Scheduling preferences; Election of the next Vice Chair
8:00 pmDinner
THURSDAY
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmEarly clinical trials
Discussion Leader: Ken Duncan (Bill & Melinda Gates Foundation)
9:00 am - 9:40 am Tim Sterling (Vanderbilt)
"TBTC Study 26"
9:40 am - 10:00 am Discussion
10:00 am Coffee Break
10:30 am - 11:10 am Bala Subramanian (AZI)
"AZD 5847 - phase I experience"
11:10 am - 11:30 am Discussion
11:30 am - 12:10 pm Bob Wallis (Pfizer)
"Biomarker acceleration of development of PNU-100480"
12:10 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 5:30 pmPoster Session III
5:30 pm - 7:30 pmClinically testing new drugs
Discussion Leader: Eric Rubin (Harvard)
5:30 pm - 6:00 pm Gerhard Walzl (Stellenbosch University)
"Biomarkers and chemotherapy"
6:00 pm - 6:15 pm Discussion
6:15 pm - 6:45 pm Willem Hanekom (University of Cape Town)
"Clinical trials - the modalities"
6:45 pm - 7:00 pm Discussion
7:00 pm - 7:30 pm Chris Lipinski (Melior Discovery)
"Where is TB drug discovery today?"
8:00 pmDinner
FRIDAY
7:30 am - 8:30 amBreakfast
9:00 amDeparture

 
© 2013 Gordon Research Conferences. All Rights Reserved. Search | Contact | Terms of Use | Privacy Policy | Follow us: Facebook Twitter